| Assessment Status | Rapid Review complete |
| HTA ID | 22063 |
| Drug | Calcifediol monohydrate |
| Brand | Dnord® |
| Indication | Treatment of vitamin D deficiency (i.e., 25(OH)D levels <25 nmol/L) in adults, for the prevention of vitamin D deficiency in adults with identified risks such as in patients with malabsorption syndrome, chronic kidney disease mineral and bone disorder (CKD-MBD) or other identified risks, and as an adjuvant for the specific treatment of osteoporosis in patients with vitamin D deficiency or at risk of vitamin D deficiency. |
| Assessment Process | |
| Rapid review commissioned | 12/09/2022 |
| Rapid review completed | 13/10/2023 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that calcifediol monohydrate (Dnord®) be considered for reimbursement. |
The HSE has approved reimbursement, December 2022.